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TRPA1 mediates the hypothermic 
action of acetaminophen
Clive Gentry, David A. Andersson & Stuart Bevan
Acetaminophen (APAP) is an effective antipyretic and one of the most commonly used analgesic 
drugs. Unlike antipyretic non-steroidal anti-inflammatory drugs, APAP elicits hypothermia in addition 
to its antipyretic effect. Here we have examined the mechanisms responsible for the hypothermic 
activity of APAP. Subcutaneous, but not intrathecal, administration of APAP elicited a dose 
dependent decrease in body temperature in wildtype mice. Hypothermia was abolished in mice pre-
treated with resiniferatoxin to destroy or defunctionalize peripheral TRPV1-expressing terminals, 
but resistant to inhibition of cyclo-oxygenases. The hypothermic activity was independent of TRPV1 
since APAP evoked hypothermia was identical in wildtype and Trpv1−/− mice, and not reduced by 
administration of a maximally effective dose of a TRPV1 antagonist. In contrast, a TRPA1 antagonist 
inhibited APAP induced hypothermia and APAP was without effect on body temperature in Trpa1−/− 
mice. In a model of yeast induced pyrexia, administration of APAP evoked a marked hypothermia in 
wildtype and Trpv1−/− mice, but only restored normal body temperature in Trpa1−/− and Trpa1−/−/
Trpv1−/− mice. We conclude that TRPA1 mediates APAP evoked hypothermia.
Acetaminophen (APAP) is a widely used analgesic and antipyretic drug, but its mechanism(s) of 
action has remained elusive. Although APAP may inhibit cyclo-oxygenase (Cox-1 and Cox-2) enzymes 
at high concentrations, this is not thought to be the primary mode of action. The lack of a strong 
anti-inflammatory activity is consistent with a mechanism that does not involve cyclo-oxygenase inhi-
bition. Furthermore, APAP in combination with a COX inhibitor, such as ibuprofen, provides improved 
analgesia1 and antipyretic activity2 compared to either compound alone, suggesting that they act through 
different mechanisms.
Recent studies have led to proposals that the analgesic effects of APAP are due to actions of 
metabolites of the parent drug on sensory neuron TRP channels. The electrophilic APAP metabolite 
N-acetyl-p-benzoquinoneimine (NAPQI) is a potent TRPA1 agonist, which is formed in the spinal cord, 
in addition to the liver and kidneys3. Both APAP itself and its metabolite NAPQI exert an analgesic effect 
when administered intrathecally to wild-type mice. This analgesic effect is absent in Trpa1−/− mice as 
is the analgesic effect of systemically administered APAP3. APAP can also be metabolized to form an 
N-acylphenolamine derivative, AM404, which is a TRPV1 agonist4 that produces TRPV1 dependent 
analgesia when administered intracerebroventricularly5. APAP is an effective antipyretic agent, which 
produces a pronounced hypothermia when administered to rodents6,7 and a small hypothermic effect in 
humans8, a difference which is probably explained by the larger surface to volume ratio and higher rate 
of heat loss in smaller animals.
TRPV1 activity in vivo regulates body temperature and TRPV1 agonists such as capsaicin and resinif-
eratoxin have long been known to produce hypothermia in rodents9–11, whereas pharmacological inhibi-
tion of TRPV1 evokes a marked hyperthermia in mice and humans12. Although TRPV1 activation could 
therefore underlie the hypothermic effects of APAP, studies with TRPV1 deficient mice and a TRPV1 
antagonist indicated that APAP induced hypothermia was independent of TRPV17. In contrast, the effect 
of TRPA1 activity on body temperature has not been examined in detail. Since TRPA1 is co-expressed 
with TRPV1 by a substantial percentage of sensory neurons, stimulation of TRPA1 in these nerve fibres 
would be expected to exert a similar hypothermic effect to that seen with TRPV1 agonists. A TRPA1 
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antagonist was reported to have no hyperthermic or hypothermic effect13, but a direct effect of an antag-
onist would rely on some degree of tonic TRPA1 activity as is thought to be the case for TRPV112.
In the current study we used genetically modified mice and pharmacological tools to determine the 
contribution of TRPA1 to the hypothermic actions of APAP. Our data demonstrate that APAP evoked 
hypothermia in mice is dependent on the presence of functional TRPA1 channels. The hypothermic 
effect of APAP is lost in Trpa1−/− mice and inhibited by administration of a TRPA1 agonist.
Results
Involvement of TRPA1. We monitored the core body temperature in response to pharmacological 
treatments in mice fitted with Bio-thermo iDENTICHIPS. The basal body temperature was not signif-
icantly different between naïve wildtype and Trpa1−/− mice (Trpa1+/+ 37.8 ± 0.1°C, range 37.3–38.3; 
Trpa1−/− 37.7 ± 0.1 °C, range 37.5–38.2, p > 0.05, n = 12 groups of 6 for each genotype). Subcutaneous 
(s.c.) injections of APAP evoked a time- and dose-dependent hypothermia in C57BL/6J mice (Fig. 1A). 
This hypothermic response reached a mean amplitude of − 4.6  ±  0.4 °C 60 min after administration of 
APAP (300 mg/kg, s.c., n = 14 independent experiments, each with n ≥ 6). Importantly, when we com-
pared the hypothermic activity of APAP in Trpa1+/+ and Trpa1−/− mice, we found that APAP had no 
effect on body temperature in Trpa1−/− mice (Fig.  1B). The antinociceptive activity of APAP is medi-
ated by activation of TRPA1 channels expressed in the central terminals of sensory neurons3. However, 
intrathecal injection of 100 μ g APAP, a dose that elicit a marked analgesia3, did not alter body tempera-
ture (Fig. 1C). The absence of hypothermia after intrathecal injections of analgesic doses of APAP also 
provides evidence that hypothermia does not contribute to the measured spinal analgesic activity of 
APAP in rodents.
We investigated the contribution of peripheral sensory neurons to the APAP evoked hypother-
mia by chemically ablating the TRPV1 expressing neurons with resiniferatoxin (RTX). Subcutaneous 
administration of RTX (6.3 μ g/kg) evoked a profound long-lasting hypothermia in both wild-type and 
Trpa1−/− mice, with body temperature returning to normal after about 24 h (Fig. 1D). Subsequent treat-
ment with APAP failed to evoke a hypothermic response in RTX-treated wildtype mice and vehicle- 
and RTX-treated Trpa1−/− mice (Fig. 1E). This observation demonstrates that both nociceptive sensory 
neurons and TRPA1 are necessary for the hypothermic response to stimulation with APAP. Earlier 
Figure 1. APAP elicits TRPA1-dependent hypothermia. (A) Subcutaneous injections of APAP evoked 
a dose-dependent hypothermia in C57BL/6J mice (n = 6–12). (B) APAP (300 mg/kg) reduced the body 
temperature in Trpa1+/+ mice but was without effect in Trpa1−/− mice (n = 6–11, see panel C for key to 
the symbols). (C) Intrathecal administration of APAP (100μ g) did not reduce body temperature (n = 6). 
(D) Resiniferatoxin (RTX, 6.3 μ g/kg, s.c.) induced a profound hypothermia in Trpa1+/+ and Trpa1−/− mice 
(n = 6). (E) APAP (300 mg/kg s.c.) evoked hypothermia in non-RTX treated Trpa1+/+ mice, but was 
without effect in Trpa1−/− and RTX treated Trpa1+/+ mice (n = 6). (F) Indomethacin (10 mg/kg, s.c.) did 
not alter body temperature and did not inhibit APAP (300mg/kg) evoked hypothermia (n = 6). (G) Oral 
administration of the TRPA1 antagonist CHEM5861528 (40–300 mg/kg, 45 min before APAP) produced 
a dose-dependent inhibition of APAP evoked hypothermia (n = 6). (H) Intraperitoneal injections of the 
TRPA1 agonist cinnamaldehyde (CA, 125 mg/kg) induced a marked hypothermia in Trpa1+/+ mice, which 
was significantly reduced in Trpa1−/− mice (n = 6). Data are mean ± sem; *p < 0.05, **p < 0.01, ***p < 0.001 
compared to vehicle and †p < 0.05, ††p < 0.01, †††p < 0.001 compared to Trpa1+/+.
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investigations proposed that APAP acts by inhibiting either COX-1 or COX-214,15. However, pretreatment 
with the nonselective COX inhibitor indomethacin (10 mg/kg, s.c.) did not alter the body temperature in 
mice and also failed to influence the hypothermia evoked by APAP, (Fig. 1F), demonstrating that APAP 
acts independently of COX-1 and COX-2.
Since our earlier investigations identified activation of TRPA1 by NAPQI formed from APAP as an 
analgesic mechanism of action3, we examined whether the APAP induced hypothermia could be pre-
vented by treatment with a pharmacological inhibitor of TRPA1. Treatment with the selective TRPA1 
inhibitor CHEM5861528 (40–300 mg/kg, p.o.) had no acute effect on body temperature in wild-type 
mice (vehicle 37.8 ± 0.1 °C, n = 18; CHEM5861528 40 mg/kg 37.8 ± 0.1 °C, n = 6; 100 mg/kg 38.0 ± 0.1 °C, 
n = 6; 300 mg/kg 37.7 ± 0.2 °C, n = 6; p > 0.05) but pre-treatment with CHEM5861528 produced a 
dose-dependent inhibition of the APAP induced hypothermia. At the highest dose tested the effects of 
APAP were essentially abolished (Fig. 1G).
APAP is metabolized to NAPQI and benzoquinone which are both TRPA1 agonists. We therefore 
examined if other TRPA1 agonists evoke hypothermia. Cinnamaldehyde (125 mg/kg) was administered 
intraperitoneally to Trpa1−/− and wild-type mice. A large reduction in body temperature was noted in 
wild-type mice, and this was greatly reduced, although not abolished, in the Trpa1−/− mice (Fig. 1H).
Involvement of TRPV1. Since TRPV1 inhibition evokes hyperthermia16,17 and TRPV1 activation 
elicits hypothermia, we re-evaluated the effects of APAP in wild-type mice treated with the TRPV1 
antagonist BCTP18, and in Trpv1−/− mice. The basal body temperature was not different in Trpv1+/+ 
and Trpv1−/− mice (Trpv1+/+ 37.8 ± 0.1 °C; Trpv1−/− 37.8 ± 0.1 °C, p > 0.2, n = 11 groups of 6 for each 
genotype). BCTP (30 mg/kg p.o.) evoked a small degree of hyperthermia in Trpv1+/+ mice but did not 
inhibit the hypothermia evoked by subsequent administration of APAP (Fig. 2A). In fact the reduction in 
body temperature was larger in mice treated with the TRPV1 antagonist, since APAP reduced the body 
temperature to the same level in mice treated with BCTP or vehicle. Similarly APAP exerted a robust 
hypothermic effect in Trpv1−/− mice that was at least as large as that observed in wild-type littermates 
(Fig. 2B). These observations confirm the results of Ayoub et al.7, which demonstrated that TRPV1 is not 
involved in APAP evoked hypothermia.
Effects on yeast-induced fever. We next investigated the importance of TRPA1 or TRPV1 for the 
antipyretic activity of APAP. Pyrexia was induced by subcutaneous administration of yeast (2 g/kg in 
saline). Such a treatment resulted in an increase in body temperature of approximately 1 °C in wild-type 
mice and in mice lacking functional TRPV1 or TRPA1 (Fig.  3). This differs from the findings of Iida, 
et al.19 who found a reduced hyperthermia in Trpv1−/− mice after intraperitoneal injection of lipopoly-
saccharide. Subsequent administration of APAP reduced body temperature and produced a robust hypo-
thermia in both wildtype and Trpv1−/− mice (Fig. 3A). In contrast, while the strong hypothermic effect 
of APAP was absent in Trpa1−/− mice, the anti-pyretic effect of APAP was still evident, demonstrating 
Figure 2. APAP induces hypothermia independently of TRPV1. (A) Oral administration of the TRPV1 
antagonist BCTP (30 mg/kg) elicited hyperthermia in C57BL/6J mice (n = 6), but did not inhibit the 
hypothermia produced by a subsequent dose of APAP (300 mg/kg). (B) APAP (300 mg/kg) evoked identical 
hypothermia in Trpv1+/+ and Trpv1−/− mice (n = 6). Data are mean ± sem; *p < 0.05, **p < 0.01, ***p < 0.001 
compared to vehicle (ANOVA followed by Tukey’s HSD test).
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that APAP produces antipyretic and hypothermic effects through distinct and independent mechanisms 
(Fig. 3B).
As it is possible that the anti-pyretic effect of APAP observed in Trpa1−/− mice was due to an action 
on TRPV14,5,20, we also examined the effects of APAP in yeast treated mice lacking both TRPV1 and 
TRPA1 (Fig.  4A). The basal body temperature of Trpa1−/−/Trpv1−/− mice was slightly, but not signifi-
cantly, higher than in matched wildtype control groups (Trpa1+/+/Trpv1+/+ 37.5 ± 0.2, range 36.9–37.9; 
Trpa1−/−/Trpv1−/− 37.9 ± 0.3, range 37.1–38.6, p = 0.19, n = 7 groups of 6 mice of each genotype). Yeast 
administration evoked a hyperthermic response in double knockout (Trpa1−/−/Trpv1−/−) mice that was 
similar in magnitude to that seen in wild-type mice. Subsequent administration of APAP reduced body 
temperature to normal levels indicating that the anti-pyretic effects of APAP were still operational in 
these double knockout mice.
APAP has been proposed to exert some of its actions through inhibition of cyclo-oxygenase enzymes, 
despite displaying a relatively modest affinity as a COX inhibitor compared to those of NSAIDs14,15. To 
determine whether the antipyrexia, unlike the hypothermia, can be explained by APAP inhibition of COX, 
we examined the effect of APAP and indomethacin in Trpa1−/−/Trpv1−/− mice made hyperthermic by 
yeast administration. Wildtype and Trpa1−/−/Trpv1−/− mice were injected with indomethacin (10 mg/kg, 
s.c.) 18 h after administration of yeast and 1 hour before administration of vehicle or APAP (Fig. 4B,C). 
Indomethacin reduced body temperature by approximately 1 °C in both wild-type and Trpa1−/−/Trpv1−/− 
mice thereby reversing the pyrexia. Subsequent administration of APAP evoked the typical hypothermia 
in wild-type mice but had no significant effect on body temperature in Trpa1−/−/Trpv1−/− mice. In 
the double knockout mice a small further reduction in temperature was noted after APAP treatment 
(Fig. 4C), but a similar reduction was noted in the vehicle treated group (Fig. 4B), indicating that this 
small hypothermic effect is independent of APAP but may instead be caused by the continued action of 
indomethacin.
Is TRPA1 responsible for the hypothermic effects of other agents? A number of other hypo-
thermic agents have been reported to act as TRPA1 agonists. These include some cannabinoid receptor 
ligands, morphine and isoflurane.
A reduction in core body temperature is a well known response to cannabinoid receptor 1 (CB1) 
agonists21–23 and several naturally occurring and synthetic CB1 agonists have been shown to be TRPA1 
agonists3,24–27. We therefore compared the effects of WIN55,212-2 on body temperature in Trpa1−/− mice 
and wild-type littermates. WIN55,212-2 (3 mg/kg s.c.) evoked similar reductions (6–7 °C) in body tem-
perature in both genotypes that lasted for at least 3 hours (Fig. 5A).
Morphine can lower body temperature in a number of species, notably at higher doses28 and at high 
concentrations acts as a TRPA1 agonist29. Sub-cutaneous administration of 10 mg/kg morphine lowered 
Figure 3. Antipyretic and hypothermic activity of APAP in yeast induced hyperthermia. Administration 
of yeast (2 g/kg) produced hyperthermia in wildtype, Trpv1−/− and Trpa1−/− mice. (A) APAP (300 mg/
kg) produced hypothermia in both hyperthermic Trpv1+/+ and Trpv1−/− mice (n = 8). (B) APAP produced 
hypothermia in Trpa1+/+ mice, but acted as an antipyretic, restoring normal, pre-yeast injection, temperature 
in Trpa1−/− mice. Dashed lines indicate pre-yeast body temperature. Data are mean ± sem; *p < 0.05, 
**p < 0.01, ***p < 0.001 compared to pre-yeast injection and ††p < 0.01, †††p < 0.001 compared to Trpa1+/+ 
(ANOVA followed by Tukey’s HSD test). For clarity, some symbols indicating statistical significance have 
been omitted from (B).
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the body temperature of wild-type mice by 5 °C after 45–60 minutes and the amplitude and duration of 
the hypothermic response was not significantly different in Trpa1−/− mice (Fig. 5B).
Isoflurane and other irritant general anaesthetics act as TRPA1 agonists30,31 and produce hypothermia 
in humans and rodents32–35. We therefore examined body temperature during isoflurane anaesthesia in 
wild-type and Trpa1−/− mice. Isoflurane elicited a similar hypothermia of short duration in both geno-
types (Fig. 5C), consistent with a TRPA1 independent mechanism.
Discussion
The mechanisms responsible for the analgesic and antipyretic actions of APAP have been the subject of 
investigation for many decades. Recent studies have concluded that APAP metabolites acting on TRP 
channels are important for the analgesic actions of the drug. Accordingly, APAP analgesia has been 
ascribed to AM404 activation of TRPV1 in the central nervous system4,5,20 and activation of TRPA1 in 
the spinal cord by local formation of the electrophilic NAPQI3. Other studies have suggested that the 
Figure 4. Effect of APAP and indomethacin in hyperthermic Trpa1−/−/Trpv1−/− mice.  
(A–C) Administration of yeast (2 g/kg) produced hyperthermia in wildtype and Trpa1−/−/Trpv1−/− mice.  
(A) APAP (300 mg/kg) evoked hypothermia in wildtype mice, but only restored normal body temperature 
in Trpa1−/−/Trpv1−/− mice (n = 6). (B) The antipyretic indomethacin (30 mg/kg) restored pre-yeast injection 
temperature in wildtype and Trpa1−/−/Trpv1−/− mice (n = 6). In Trpa1−/−/Trpv1−/− mice, this was later 
followed by a slow reduction in body temperature. (C) Adminstration of APAP (300 mg/kg) 1h after 
indomethacin (30 mg/kg) rapidly elicited hypothermia in wildtype, but not Trpa1−/−/Trpv1−/− mice (n = 6). 
The slow reduction in body temperature in Trpa1−/−/Trpv1−/− mice was not different from that seen in  
(B) in animals receiving vehicle instead of APAP. Data are mean ± sem; *p < 0.05, **p < 0.01, ***p < 0.001 
compared to pre-yeast injection and †p < 0.05, ††p < 0.01, †††p < 0.001 compared to Trpa1+/+ (ANOVA 
followed by Tukey’s HSD test).
Figure 5. Hypothermic effects of other agents. The CB1 and CB2 receptor agonist WIN55,212-2  
(A), the opioid receptor agonist morphine (B) and the general anaesthetic isoflurane (C) produced a marked 
hypothermia in Trpa1+/+ and Trpa1−/− mice (n = 6).
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cannabinoid receptor system contributes to APAP analgesia36,37. The antipyretic and hypothermic actions 
of APAP are not well understood. However, the findings that the hypothermic effects of APAP were 
retained in Trpv1−/− mice as well as in mice lacking cannabinoid receptor 1 rule out a role for these 
pathways in APAP-evoked hypothermia7.
Our studies demonstrated that APAP produced a profound hypothermia in wild-type mice that was 
dependent on the presence of functional TRPA1 channels. APAP-evoked hypothermia was absent in 
Trpa1−/− mice and inhibited by prior systemic treatment with a TRPA1 antagonist. The locus of hypo-
thermic action is likely to be TRPA1 expressed in peripheral sensory neurons, since the response could 
be abolished by RTX mediated chemical ablation of TRPV1 containing sensory neurons. Body tempera-
ture is controlled by peripheral sensory input to the CNS as well as by central thermoregulatory mecha-
nisms9,38,39. Recent studies on TRPV1 antagonists have highlighted the importance of TRPV1 expressing 
peripheral sensory nerves for temperature regulation. Stimulation of TRPV1 with systemic capsaicin 
treatment leads to hypothermia9,38, while administration of many (but not all) TRPV1 antagonists causes 
hyperthermia12,40–42. Functional ablation of these peripheral sensory neurons by prior administration of 
the ultrapotent TRPV1 agonist RTX results in a loss of TRPV1 mediated temperature changes40.
In our studies the hypothermic effects of APAP were abolished by a similar systemic treatment with 
RTX. However, the effect of APAP could not be ascribed to TRPV1 agonism as hypothermia was retained 
in Trpv1−/− mice and unaffected by systemic administration of a dose of a TRPV1 antagonist that exerts 
a maximal analgesic effect18, in agreement with previous studies7. TRPA1 is predominantly expressed in 
TRPV1 containing sensory neurons43. The functional ablation of the TRPV1-expressing neurons by RTX 
will therefore have severely compromised or abolished TRPA1 responses, explaining the very marked 
effect of RTX treatment on APAP evoked temperature changes.
Intraperitoneal administration of the TRPA1 agonist cinnamaldehyde produced a significant hypo-
thermia in wild-type mice that was greatly reduced, although not completely abolished, in Trpa1−/− 
mice. This finding demonstrates that TRPA1 agonism can influence body temperature, almost certainly 
because TRPA1 is co-localized in TRPV1 containing thermoregulatory sensory nerves. In addition, it is 
consistent with the hypothesis that activation of TRPA1 by electrophilic APAP metabolites is responsible 
for the observed hypothermia. Electrophilic APAP metabolites are formed in the liver and liver afferent 
neurons are therefore prime candidates for the site of action. Importantly, we found that genetic or 
pharmacological blockade of TRPA1 does not produce hyperthermia in rodents, in agreement with an 
earlier report44. This observation indicates that TRPA1, unlike TRPV1, does not have a significant tonic 
activity in thermosensitive afferent fibres under normal conditions12.
Although TRPA1 is important for the hypothermic effects of APAP, our studies suggest that other 
mechanisms contribute to its antipyretic effects. Yeast induced hyperthermia was of a similar magnitude 
in wild-type, Trpa1−/− and Trpa1−/−/Trpv1−/− (double knockout) mice. The absence of APAP evoked 
hypothermia in both Trpa1−/− and Trpa1−/−/Trpv1−/− mice allowed the antipyretic effects to be studied 
in isolation. APAP reduced the elevated body temperature to normal levels in Trpa1−/− and Trpa1−/−/
Trpv1−/− mice, indicating that neither TRP channel plays a role in the antipyretic actions of APAP.
We explored the possibility that the antipyretic effect of APAP was mediated by cyclo-oxygenase 
inhibition by examining the effect of APAP in mice pre-treated with indomethacin. In wild-type and 
Trpa1−/−/Trpv1−/− mice, indomethacin reversed the pyrexia and normalized body temperature to 
the pre-yeast levels, indicating that these TRP channels are not involved in the antipyretic effects of 
cyclo-oxygenase inhibitors. Subsequent APAP administration evoked hypothermia in wild-type mice, 
which demonstrated that cyclo-oxygenase activity is not important for this effect of APAP. In indometh-
acin pre-treated Trpa1−/−/Trpv1−/− mice, a continued small slow reduction in body temperature was 
noted after administration of either APAP or vehicle. The lack of any obvious APAP induced tempera-
ture change when the cyclo-oxygenase enzymes are already inhibited could be interpreted as evidence 
that cyclo-oxygenase inhibition underlies the antipyretic effects of APAP. However, it is possible that 
APAP had no effect because the pyrexia had been reversed and body temperature normalized by the 
indomethacin treatment.
Although the TRPA1 agonist cinnamaldehyde evoked TRPA1-dependent hypothermia, a range of 
other hypothermic agents that have been reported to act as TRPA1 agonists retained the ability to reduce 
body temperature in Trpa1−/− mice. These included the general anaesthetic isoflurane, the cannabinoid 
receptor 1 agonist WIN55,212-2 and the opioid receptor agonist morphine. Despite the common prop-
erty of TRPA1 agonism, these diverse agents must reduce body temperature primarily by other mecha-
nisms at the doses used in our experiments.
Conclusions
Our results demonstrate that activation of TRPA1 in sensory neurons mediates the hypothermic effect of 
APAP in mice. These findings support our previous identification of TRPA1 as a target for the analgesic 
activity of APAP3. Importantly, APAP does not reduce body temperature after intrathecal injections, 
demonstrating that hypothermia is not required for its spinal antinociceptive effect. The hypother-
mic effect of APAP is completely lost in Trpa1−/− mice and resistant to inhibition of cyclo-oxygenase. 
However, it is possible that APAP exerts its antipyretic activity by cyclo-oxygenase inhibition, since APAP 
reversed yeast induced hyperthermia in mice lacking both TRPA1 and TRPV1. The TRPA1 mediated 
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hypothermia may explain the improved antipyretic activity seen with combinations of APAP and the 
NSAID ibuprofen2.
Methods
Animals. All animal procedures were carried out in accordance with the UK Animals (Scientific 
Procedures) Act 1986. All experimental procedures were approved by the King’s College London Animal 
Care and Ethics Committee. Data shown are from female C57BL/6J mice or from male and female 
homozygote Trpa1−/− and Trpa1+/+ littermates. C57BL/6J mice were obtained from Charles River UK. 
TRPA1-null mice and wild-type littermates were bred from heterozygous mice provided by Drs Kelvin 
Kwan and David Corey (Harvard Medical School, Boston, MA). TRPV1–null mice were bred from 
homozygous mice obtained from the Jackson Laboratory (Bar Harbor, ME). Trpa1−/−/Trpv1−/− mice 
were generated in house by crossing the Trpa1−/− and Trpv1−/− mice.
Temperature measurements. Under general anaesthesia, the lower back of the mice was shaved. 
The mice were then implanted subcutaneously in the shoulder region with a small identification chip 
incorporating a quick reading thermometer accurate to 0.1 degree °C (idENTICHIP® with Bio-Thermo™ , 
AnimalCare Ltd. UK). The small skin incision was closed using tissue adhesive (Vetbond, 3M).
Bio-Thermo chips have many advantages over other commonly used methods for recording body 
temperature. Body temperatures can be measured repeatedly without disturbing the animals using a 
hand-held scanner. As each chip has a unique identity, they enable animals to be group housed in their 
home cages. It is less stressful than rectal temperature recording and is cheaper than radiotelemetry 
methods.
During each experiment, body temperature was recorded every 15 min for up to 45 min prior to drug 
administration to establish baseline temperatures and then post dose for up to 24 h.
Drugs. Acetaminophen (APAP, 4-Acetamidophenol; Sigma-Aldrich, UK) and morphine (Sigma-Aldrich, 
UK) were prepared in 0.9% saline (with warming for APAP). WIN55,212-2 (Tocris, UK) was made up in 
5% DMSO/5% Tween 80/0.9% saline, RTX (Sigma-Aldrich, UK) in 10% ethanol/10% Tween 80/saline, 
indomethacin (Sigma-Aldrich, UK) in 5% sodium hydrogen carbonate (pH to 7.4), cinnamaldehyde 
(Fluka) in 0.5% Tween 80/saline and brewer’s yeast; (Acros Organics) in 0.9% saline. BCTP (7-tert-butyl-
6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one) was suspended in 0.5% 
methyl cellulose. CHEM5861528 (Chembridge Corporation, USA), capsaicin (Sigma-Aldrich, UK) was 
administered in 10% DMSO/saline. Mice were exposed to isoflurane (Abbott Industries Ltd. UK) at 2.5% 
in 95%O2/5% CO2 for 5 minutes.
Data analysis. All data are presented as the mean ± sem. Plots show the change in body temperature 
from baseline readings or the raw recorded temperature. Statistical analysis was carried out on raw data 
using repeated measures ANOVA followed by post-hoc analysis using Tukey’s HSD test (p < 0.05 was set 
as the level of statistical significance).
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